About Acceleron Aktie
Our Purpose and Mission
This website serves as an informational resource for investors, researchers, and individuals seeking to understand the history and outcome of Acceleron Pharma as a publicly traded company. While Acceleron no longer exists as an independent entity following its acquisition by Merck in November 2021, the company's story offers valuable lessons for anyone interested in biopharmaceutical investing, drug development, and the dynamics of the biotech sector.
We created this resource to preserve and explain the Acceleron investment story in clear, accessible terms. Many former shareholders and prospective biotech investors seek information about what happened to XLRN stock, why Merck paid a premium to acquire the company, and what the financial and clinical outcomes were. Our goal is to provide factual, data-driven answers based on public financial disclosures, clinical trial results, and regulatory filings.
The biotech sector can be complex and opaque, particularly for individual investors without scientific backgrounds. We aim to bridge that gap by explaining both the financial and scientific aspects of Acceleron's development in plain language. Whether you're researching the company for academic purposes, evaluating a similar investment opportunity, or simply curious about what happened to your former shares, this site provides the information you need. For specific questions, visit our FAQ page, and for detailed analysis of the company's performance, see our main page.
| Year | Milestone | Significance |
|---|---|---|
| 2003 | Company founded | Established in Cambridge, MA |
| 2013 | Initial public offering | Raised $117M at $18/share |
| 2015 | Bristol Myers Squibb partnership | Collaboration on luspatercept |
| 2019 | Reblozyl FDA approval | First marketed product |
| 2020 | Sotatercept Phase 2 success | Validated PAH program |
| 2021 | Merck acquisition completed | $11.5B all-cash transaction |
Understanding the Biotech Investment Context
Acceleron's trajectory from a research-stage company to an $11.5 billion acquisition target illustrates both the opportunities and risks inherent in biotech investing. The company spent nearly 16 years developing its scientific platform and drug candidates before reaching a successful exit. During that time, it raised hundreds of millions in capital, experienced both setbacks and breakthroughs, and ultimately created substantial value for shareholders who maintained their positions through the volatility.
The biopharmaceutical industry operates differently from most other sectors. Companies can operate for years without generating revenue, investing heavily in research and development with binary outcomes—drugs either work and gain approval, or they fail and become worthless. According to data from the Biotechnology Innovation Organization, approximately 90% of drug candidates that enter clinical trials ultimately fail to gain FDA approval. This high failure rate explains both the volatility of biotech stocks and the premium valuations successful companies can command.
Acceleron succeeded where many others failed by focusing on a well-defined biological mechanism, executing rigorous clinical trials, and demonstrating meaningful benefits for patients with serious diseases. The company's approach to the TGF-beta superfamily was grounded in solid science, published in peer-reviewed journals, and validated through partnerships with major pharmaceutical companies. Understanding these factors helps explain why Merck was willing to pay $180 per share—nearly 100 times the company's annual revenue—to acquire the assets. The National Institutes of Health provides extensive resources on drug development that offer additional context for understanding the challenges Acceleron overcame.
Information Sources and Accuracy
All financial data, stock prices, and corporate milestones presented on this website are derived from publicly available sources, including SEC filings, press releases, clinical trial databases, and peer-reviewed scientific publications. We prioritize accuracy and cite authoritative sources including the Securities and Exchange Commission, FDA databases, and published research from medical journals.
Stock price information comes from historical NASDAQ data for the period when Acceleron traded under the ticker XLRN. Financial statements are based on the company's annual 10-K and quarterly 10-Q filings with the SEC. Clinical trial information is sourced from ClinicalTrials.gov, FDA approval letters, and publications in journals such as The New England Journal of Medicine. We make every effort to ensure information is current and accurate as of the dates specified.
This website is an educational resource and does not provide investment advice, medical advice, or recommendations to buy or sell securities. Acceleron Pharma no longer exists as a publicly traded company, and XLRN stock cannot be purchased. The information presented here is historical in nature and intended to help readers understand what happened to the company and its shareholders. For current investment opportunities in the biopharmaceutical sector, investors should consult with licensed financial advisors and conduct their own due diligence. Information about current biotech companies and investment considerations can be found through resources like the Biotechnology Innovation Organization.
| Source Type | Specific Resource | Data Provided |
|---|---|---|
| Regulatory Filings | SEC EDGAR Database | Financial statements, merger documents |
| Clinical Trials | ClinicalTrials.gov | Trial designs, enrollment, results |
| Stock Market | NASDAQ Historical Data | Share prices, trading volume |
| Scientific Publications | PubMed/Medical Journals | Clinical data, mechanism of action |
| Corporate Communications | Press Releases/Investor Relations | Announcements, guidance, milestones |